|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM373967187 |
| 003 |
DE-627 |
| 005 |
20250306081128.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240623s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.110289
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1245.xml
|
| 035 |
|
|
|a (DE-627)NLM373967187
|
| 035 |
|
|
|a (NLM)38908769
|
| 035 |
|
|
|a (PII)S1521-6616(24)00398-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lee, Hyun
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer
|b Clinical potential and efficacy in EGFR mutation subsets
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.07.2024
|
| 500 |
|
|
|a Date Revised 22.07.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2024. Published by Elsevier Inc.
|
| 520 |
|
|
|a Our study aimed to expand tumor-infiltrating lymphocytes (TILs) from primary non-small cell lung cancers (NSCLCs) and evaluate their reactivity against tumor cells. We expanded TILs from 103 primary NSCLCs using histopathological analysis, flow cytometry, IFN-γ release assays, cell-mediated cytotoxicity assays, and in vivo efficacy tests. TIL expansion was observed in all cases, regardless of EGFR mutation status. There was also an increase in the median CD4+/CD8+ ratio during expansion. In post-rapid expansion protocol (REP) TILs, 13 out of 16 cases, including all three cases with EGFR mutations, exhibited a two-fold or greater increase in IFN-γ secretion. The cytotoxicity assay revealed enhanced tumor cell death in three of the seven cases, two of which had EGFR mutations. In vivo functional testing in a patient-derived xenograft model showed a reduction in tumor volume. The anti-tumor activity of post-REP TILs underscores their potential as a therapeutic option for advanced NSCLC, irrespective of mutation status
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Adoptive cell therapy
|
| 650 |
|
4 |
|a EGFR mutation
|
| 650 |
|
4 |
|a Non-small cell lung cancer
|
| 650 |
|
4 |
|a Tumor-infiltrating lymphocytes
|
| 650 |
|
7 |
|a ErbB Receptors
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 650 |
|
7 |
|a EGFR protein, human
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 650 |
|
7 |
|a Interferon-gamma
|2 NLM
|
| 650 |
|
7 |
|a 82115-62-6
|2 NLM
|
| 700 |
1 |
|
|a Lee, Miseon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lim, Chae Lyul
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Park, Hye Seon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Song, In Hye
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jeong, Byung-Kwan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Dong Kwan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Yong-Hee
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Choi, Sehoon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Geun Dong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Sae Byul
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jung, SungWook
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gong, Gyungyub
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Sung-Bae
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yoo, Changhoon
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kim, Joo Young
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Hee Jin
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 265(2024) vom: 01. Aug., Seite 110289
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnas
|
| 773 |
1 |
8 |
|g volume:265
|g year:2024
|g day:01
|g month:08
|g pages:110289
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.110289
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 265
|j 2024
|b 01
|c 08
|h 110289
|